Nordson (NDSN) Q3 2026 earnings summary

Executive summary

• Achieved record Q3 sales of $818 million, up 10% year-over-year, with 12% organic growth across all segments and all segments contributing to growth.

• Adjusted EPS reached an all-time high of $3.25, up 19% from prior year, and GAAP EPS was $2.73, up 23%.

• Net income for the quarter was $153 million, with strong performance in electronics, packaging, and medical product lines.

• Backlog increased 35% year-over-year, driven by broad-based order entry momentum, especially in Advanced Technology Solutions (ATS) and Medical and Fluid Solutions (MFS).

• Free cash flow was $237 million for the quarter, with conversion well over 100% of net income, supporting shareholder returns and reinvestment.

Financial highlights

• Q3 sales: $818 million (+10% YoY); organic growth: 12%.

• EBITDA for Q3: $262 million (+10% YoY), margin 32%.

• Gross margin for the quarter was 55.5%, up from 54.8% a year ago.

• Adjusted operating profit: $226 million (+13% YoY), 28% of sales.

• Free cash flow conversion rate: 144% in Q3.

Outlook and guidance

• Full-year sales guidance raised to $3.035–$3.075 billion; adjusted EPS guidance increased to $11.80–$12.00.

• Backlog up 35% YoY, supporting confidence in Q4 and into 2027.

• Management expects continued top-tier growth with leading margins and returns, supported by a scalable growth framework and ongoing investments in innovation.

• Tax rate expected to remain near 18% long-term.

• FX impact assumed neutral for Q4.